Trials / Completed
CompletedNCT04574362
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
BHV3000-310: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,648 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is to determine whether BHV3000 (rimegepant) 75mg is safe and effictive as a treatment for acute migraine in Chinese and Korean patients
Detailed description
Biohaven Pharmaceuticals, Inc. is the agent for BioShin Limited, the sponsor of the studies in China and Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimegepant | One 75mg orally disintegrating tablet |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2020-10-22
- Primary completion
- 2021-11-24
- Completion
- 2021-12-16
- First posted
- 2020-10-05
- Last updated
- 2023-12-14
- Results posted
- 2023-12-14
Locations
90 sites across 2 countries: China, South Korea
Source: ClinicalTrials.gov record NCT04574362. Inclusion in this directory is not an endorsement.